IP Library Granted Patent US 7,932,039
Granted Patent B2
US 7,932,039 · App. 12/360,819 · Granted Apr 26, 2011

Nucleic acid detection assays employing blocker oligonucleotides

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,932,039
App. No.
12/360,819
Granted
Apr 26, 2011
Kind
B2
Abstract

The present invention provides methods, compositions, and kits for detecting the presence or absence of target sequences in a sample, where the sample also contains interfering sequences that are similar or identical to the target sequences. In particular, the present invention provides blocker oligonucleotides that at least partially inhibit the formation of invasive cleavage structures with the interfering sequences but do not substantially inhibit the formation of invasive cleavage structures with the target sequences.

Claims (24)

1. A composition, comprising:

a) first and second nucleic acid molecules, wherein said first and second nucleic acid molecules are configured to form a first invasive cleavage structure with a target sequence within a target region, and wherein said first and second nucleic acid molecules are also able to form a second invasive cleavage structure with an interfering sequence within an interfering region, and

b) blocker oligonucleotides configured to at least partially hybridize with said interfering sequence such that formation of said second invasive cleavage structure is at least partially inhibited.

2. The composition of claim 1 , further comprising c) a cleavage agent, wherein said cleavage agent is capable of cleaving said first nucleic acid molecules when said first nucleic acid molecules form an invasive cleavage structure comprising said second nucleic acid molecules and said target sequence or said interfering sequence.

3. The composition of claim 1 , further comprising said target region.

4. The composition of claim 3 , further comprising said interfering region.

5. The composition of claim 1 , wherein said first and second nucleic acid molecules and said blocker oligonucleotides are configured such that at least 70 percent of invasive cleavage structures formed in the presence of said target sequence and said interfering sequence are said first invasive cleavage structures.

6. The composition of claim 1 , wherein the melting temperature of said blocker oligonucleotides when hybridized to said interfering sequence is greater than the melting temperature of said second nucleic acid molecules when hybridized to said interfering sequence.

7. The composition of claim 1 , wherein said blocker oligonucleotides are configured to hybridize to at least a portion of said interfering sequence and to at least a portion of said interfering region that is not part of said interfering sequence.

8. The composition of claim 1 , wherein said first nucleic acid molecules comprise a 5′ portion and a 3′ portion, wherein said 3′ portion is configured to hybridize to said target sequence, and wherein said 5′ portion is configured to not hybridize to said target sequence.

9. The composition of claim 1 , wherein said second nucleic acid molecules comprise a 5′ portion and a 3′ portion, wherein said 5′ portion is configured to hybridize to said target sequence, and wherein said 3′ portion is configured to not hybridize to said target sequence.

10. The composition of claim 1 , wherein said interfering sequence is identical to said target sequence.

11. The composition of claim 1 , wherein said interfering sequence is at least 97 percent homologous to said target sequence.

12. The composition of claim 1 , wherein said interfering sequence has five or fewer nucleotide base difference compared to said target sequence.

13. The composition of claim 1 , wherein said target sequence and said interfering sequence are each at least 15 bases in length.

14. The composition of claim 1 , wherein the Tm of said second oligonucleotide with regard to said interfering region less than 63° C.

15. The composition of claim 1 , wherein said target region comprises a first gene, and wherein said interfering region comprises a first pseudo-gene.

16. The composition of claim 1 , wherein said target sequence comprises a targeted polymorphic sequence.

17. The composition of claim 16 , wherein said targeted polymorphic sequence is a single nucleotide polymorphism.

18. A composition for analyzing a target sequence, comprising:

i) first and second nucleic acid molecules, wherein said first and second nucleic acid molecules are configured to form a first invasive cleavage structure with a target sequence, and wherein said first and second nucleic acid molecules are also able to form a second invasive cleavage structure with an interfering sequence;

ii) a sample comprising: A) a target region suspected of containing said target sequence, and B) an interfering region comprising said interfering sequence;

iii) a cleavage agent; and

iv) blocker oligonucleotides configured to at least partially hybridize with said interfering region such that formation of said second invasive cleavage structure is at least partially inhibited.

Assignments (10)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
MERGER Recorded Oct 23, 2015
From: THIRD WAVE AGBIO, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: GEN-PROBE INCORPORATED
Reel/Frame 036934/0796 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →
TERMINATION OF PATENT SECURITY AGREEMENTS AND RELEASE OF SECURITY INTERESTS Recorded Aug 26, 2010
From: GOLDMAN SACHS CREDIT PARTNERS, L.P., AS COLLATERAL AGENT
To: HOLOGIC, INC.; R2 TECHNOLOGY, INC.; SUROS SURGICAL SYSTEMS, INC.; BIOLUCENT, LLC; DIRECT RADIOGRAPHY CORP.; CYTYC SURGICAL PRODUCTS II LIMITED PARTNERSHIP; CYTYC SURGICAL PRODUCTS LIMITED PARTNERSHIP; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS III, INC.; CYTYC PRENATAL PRODUCTS CORP.; THIRD WAVE TECHNOLOGIES, INC.
Reel/Frame 024892/0001 →
FIFTH SUPPLEMENT TO PATENT SECURITY AGREEMENT Recorded Feb 19, 2009
From: THIRD WAVE TECHNOLOGIES, INC.
To: GOLDMAN SACHS CREDIT PARTNERS L.P., AS COLLATERAL AGENT
Reel/Frame 022279/0674 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2009
From: AGARWAL, POONAM; KWIATKOWSKI, ROBERT W., JR.
To: THIRD WAVE TECHNOLOGIES, INC.
Reel/Frame 022166/0537 →